Updated
Updated · Fortune · Aug 3
ChronicleBio Launches $400 Home Blood Draws for Chronic Disease Research, Free for First 250
Updated
Updated · Fortune · Aug 3

ChronicleBio Launches $400 Home Blood Draws for Chronic Disease Research, Free for First 250

1 articles · Updated · Fortune · Aug 3

Summary

  • August 11 is the start date for ChronicleBio’s U.S. sign-up link for mobile blood draws, letting people with certain chronic illnesses give samples from home in exchange for a detailed condition report.
  • The company says home collection should widen access to bedridden patients and expand the biological dataset it uses with OpenAI and Anthropic models to identify disease subtypes that standard diagnoses miss.
  • ChronicleBio has already logged 890 blood draws from 709 patients across Utah, Arizona, Texas and India, building a biobank of more than 3,500 tubes and extracting 153 terabytes of blood data.
  • Fidji Simo said the startup has identified 5 biologically distinct sub-diseases within symptom-based conditions such as POTS and plans to begin testing existing drugs on its patient population before year-end.
  • Backed by $15 million, ChronicleBio argues richer blood-based data could improve chronic-disease drug trials, which often fail when one treatment is tested across biologically different patient groups.

Insights

Will paying $400 for an at-home blood test actually cure chronic fatigue, or simply feed a massive corporate AI database?
Can an AI executive's personal battle with POTS finally decode the biological mysteries of chronic illnesses that traditional medicine has ignored?